MedTrace Logo

Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)

NCT04042155 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1600

Last updated 2024-02-28

No results posted yet for this study

Summary

MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Design: single-center, observational, prospective, uncontrolled study of anticoagulated patients with any direct oral anticoagulant (DOAC) with atrial fibrillation or venous thromboembolism to determine the incidence of serious complications (thromboembolic or hemorrhagic) in real life

Conditions

Interventions

DRUG

dabigatran, rivaroxaban, apixaban or edoxaban

Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.

Sponsors & Collaborators

  • Daiichi Sankyo

    collaborator INDUSTRY

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Principal Investigators

  • Juan C Souto, MD, PhD · Hospital de la Santa creu i Sant Pau - Barcelona

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-29
Primary Completion
2024-08-31
Completion
2024-08-31
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04042155 on ClinicalTrials.gov